ABLATION MOA
Research type
Research Study
Full title
Evaluation of Mechanism of Action of Novel Bronchoscopic Ablation Techniques
IRAS ID
350533
Contact name
Pallav Shah
Contact email
Sponsor organisation
Guy's and St Thomas' NHS Foundation Trust
Duration of Study in the UK
4 years, 0 months, 0 days
Research summary
Lung cancer is the leading cause of malignant-related death worldwide, accounting for the highest mortality rates in both men and women and is often diagnosed at advanced stages when treatment options are limited. Bronshoscopic ablation techniques for management of lung cancer may achieve an effective and less invasive approach than the traditionally used strategies. New treatment strategies in management of lung cancer is desperately needed and the novel bronchoscopic treatments may reduce morbidity and mortality, patient distress and healthcare costs. Understanding how they work is essential.
We plan to study new bronchoscopic ablation techniques for lung cancer including microwave ablation and irreversible electroporation (IRE). We need to learn more about this treatment including how it affects the tumour tissue and the rest of the body.
This will be an add-on study to bronchoscopic microwave ablation and irreversible electroporation studies. This add-on study is planned to take 48 months. During this time, patients will have in-hospital visits where possible coinciding with their already planned clinical or research appointments. We will take blood tests to assess how the immune system responds to these treatments and whether they induce ‘immune priming’, which can result in the body killing the residual tumour cells after ablation, inhibiting local recurrence and treating distant metastasis. If EBUS or bronchoscopy is planned for clinical purposes, extra tissue samples may also be taken to study the immune cells in the lymph nodes and lung tissue to enable us better understand this mechanism of action.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
25/YH/0233
Date of REC Opinion
24 Oct 2025
REC opinion
Favourable Opinion